pdate of the EORTC QLQ-PAN26 questionnaire for the assessment of health-related quality of life (HRQoL) in patients with pancreatic adenocarcinoma.

Swansea University0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年8月2日

试验速览

暂无简介。

•Health Care Professional inclusion criteria â?? Phase 1b and 1d:
•a. Adults aged >=18 years
•b. Clinician, nurse, or other HCP (e.g., advanced practitioner) with specific senior expertise and experience ( >2 years) in the treatment and care of patients with PDAC (e.g., oncology, surgery, radiotherapy, specialist nurse, palliative care).
•c. Willingness to undertake an interview or written questionnaire in English.
•Patient participants inclusion criteria - Phase 1c and 1d
•a.Adults aged >=18 years
•b.Histologically proven as adenocarcinoma of the pancreas (head, body, tail) with disease stages I-IV.
•c.Are aware of their diagnosis and treatment plan.
•d.Patients receiving treatment (either currently or within the last 12 months) including a systemic treatment (chemotherapy, radiotherapy or chemoradiotherapy), biological and immunotherapy), surgical resection, and radiotherapy or receiving supportive or palliative care.
•e.Patients who are willing and able to give fully informed consent to participate.
•f.Patients who are currently enrolled in a clinical trial of a therapeutic agent (phase I-II) whose enrolment in this study is permitted under the trial eligibility criteria AND where any concurrent quality of life assessment (e.g., as part of the trial endpoint) will not affect the results of the current study.

•Health Care Professional exclusion criteria - Phase 1b and 1d:
•a. HCPs under 18 years of age.
•b. HCPs with limited experience ( <2 years).
•Patient participants exclusion criteria - Phase 1c and 1d:
•a. Patients under 18 years of age.
•b. Patients with concurrent malignancy.
•c. Patients enrolled in other quality of life studies which will affect the results of the current study.

发起方